FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3026111010> ?p ?o ?g. }

• W3026111010 endingPage "823" @default.
• W3026111010 startingPage "811" @default.
• W3026111010 abstract "Exosomes secreted by tumor cells can be regarded as carriers of tumor-associated antigens and have potential value in tumor immunotherapy. The aim of this study was to evaluate the antitumor efficacy of a novel exosomal vaccine (interferon-γ [IFN-γ]-modified exosomal vaccine) in prostate cancer.Prostate cancer cell-derived exosomes were used to prepare the exosomal vaccine using our protein-anchoring technique. The immunogenicity and therapeutic efficacy of the exosomes was evaluated by measuring the effects of the exosomal vaccine on M1 macrophage differentiation, the ability of macrophages to engulf the exosomes, the production of antibodies against exosomes, and tumor angiogenesis and metastasis, and tumor growth.The IFN-γ fusion protein was efficiently anchored on the surface of prostate cancer cell-derived exosomes and retained its bioactivity. The IFN-γ-exosomal vaccine increased the number of M1 macrophages, enhanced the ability of M1 macrophages to engulf RM-1 cell-derived exosomes, and induced the production of specific antibodies against exosomes. The exosomal vaccine downregulated the expression of vascular endothelial growth factor receptor 2 and attenuated the effect of exosomes in promoting tumor metastasis. The proportions of CD4+ , CD8+ , and IFN-γ+ CD8+ T cells in the exosomal vaccine group were the highest among the four groups. Interestingly, the IFN-γ-exosomal vaccine decreased the percentage of Tregs and downregulated the expression of programed death-ligand 1 and indoleamine 2, 3-dioxygenase 1 in the tumor environment. The exosomal vaccine significantly inhibited tumor growth and prolonged the survival time of mice with prostate cancer. The exosomal and tumor cell vaccines had a good synergistic effect in promoting tumor immunity.The novel exosomal vaccine induced an immune response that cleared prostate cancer cell-derived exosomes, thereby eliminating the regulatory effect of the exosomes. This study may provide experimental evidence for the use of exosomes as a therapeutic tool or target in immunotherapy for human prostate cancer." @default.
• W3026111010 created "2020-05-29" @default.
• W3026111010 creator A5006794114 @default.
• W3026111010 creator A5013129858 @default.
• W3026111010 creator A5028558643 @default.
• W3026111010 creator A5051881032 @default.
• W3026111010 creator A5056592525 @default.
• W3026111010 creator A5060642728 @default.
• W3026111010 creator A5072911141 @default.
• W3026111010 date "2020-05-19" @default.
• W3026111010 modified "2023-10-02" @default.
• W3026111010 title "Antitumor efficacy of interferon‐γ‐modified exosomal vaccine in prostate cancer" @default.
• W3026111010 cites W1488814076 @default.
• W3026111010 cites W1824585857 @default.
• W3026111010 cites W1990467165 @default.
• W3026111010 cites W2068238023 @default.
• W3026111010 cites W2158070898 @default.
• W3026111010 cites W2177833865 @default.
• W3026111010 cites W2265131395 @default.
• W3026111010 cites W2326375536 @default.
• W3026111010 cites W2340119325 @default.
• W3026111010 cites W2444378544 @default.
• W3026111010 cites W2471135848 @default.
• W3026111010 cites W2500688572 @default.
• W3026111010 cites W2594614289 @default.
• W3026111010 cites W2598910330 @default.
• W3026111010 cites W2605111984 @default.
• W3026111010 cites W2617615447 @default.
• W3026111010 cites W2618366318 @default.
• W3026111010 cites W2739501186 @default.
• W3026111010 cites W2742471933 @default.
• W3026111010 cites W2749228483 @default.
• W3026111010 cites W2756553142 @default.
• W3026111010 cites W2772792890 @default.
• W3026111010 cites W2775672218 @default.
• W3026111010 cites W2781525129 @default.
• W3026111010 cites W2792427092 @default.
• W3026111010 cites W2803014560 @default.
• W3026111010 cites W2888555926 @default.
• W3026111010 cites W2889341191 @default.
• W3026111010 cites W2898056876 @default.
• W3026111010 cites W2916372295 @default.
• W3026111010 cites W2923990740 @default.
• W3026111010 cites W2969934413 @default.
• W3026111010 cites W2973738434 @default.
• W3026111010 cites W2980967627 @default.
• W3026111010 doi "https://doi.org/10.1002/pros.23996" @default.
• W3026111010 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32427375" @default.
• W3026111010 hasPublicationYear "2020" @default.
• W3026111010 type Work @default.
• W3026111010 sameAs 3026111010 @default.
• W3026111010 citedByCount "28" @default.
• W3026111010 countsByYear W30261110102020 @default.
• W3026111010 countsByYear W30261110102021 @default.
• W3026111010 countsByYear W30261110102022 @default.
• W3026111010 countsByYear W30261110102023 @default.
• W3026111010 crossrefType "journal-article" @default.
• W3026111010 hasAuthorship W3026111010A5006794114 @default.
• W3026111010 hasAuthorship W3026111010A5013129858 @default.
• W3026111010 hasAuthorship W3026111010A5028558643 @default.
• W3026111010 hasAuthorship W3026111010A5051881032 @default.
• W3026111010 hasAuthorship W3026111010A5056592525 @default.
• W3026111010 hasAuthorship W3026111010A5060642728 @default.
• W3026111010 hasAuthorship W3026111010A5072911141 @default.
• W3026111010 hasConcept C104317684 @default.
• W3026111010 hasConcept C121608353 @default.
• W3026111010 hasConcept C126322002 @default.
• W3026111010 hasConcept C145059251 @default.
• W3026111010 hasConcept C167672396 @default.
• W3026111010 hasConcept C203014093 @default.
• W3026111010 hasConcept C20518536 @default.
• W3026111010 hasConcept C2776107976 @default.
• W3026111010 hasConcept C2776178377 @default.
• W3026111010 hasConcept C2777701055 @default.
• W3026111010 hasConcept C2778378633 @default.
• W3026111010 hasConcept C2779013556 @default.
• W3026111010 hasConcept C2780192828 @default.
• W3026111010 hasConcept C2780394083 @default.
• W3026111010 hasConcept C2780868878 @default.
• W3026111010 hasConcept C2781261824 @default.
• W3026111010 hasConcept C502942594 @default.
• W3026111010 hasConcept C55493867 @default.
• W3026111010 hasConcept C71924100 @default.
• W3026111010 hasConcept C86803240 @default.
• W3026111010 hasConcept C8891405 @default.
• W3026111010 hasConceptScore W3026111010C104317684 @default.
• W3026111010 hasConceptScore W3026111010C121608353 @default.
• W3026111010 hasConceptScore W3026111010C126322002 @default.
• W3026111010 hasConceptScore W3026111010C145059251 @default.
• W3026111010 hasConceptScore W3026111010C167672396 @default.
• W3026111010 hasConceptScore W3026111010C203014093 @default.
• W3026111010 hasConceptScore W3026111010C20518536 @default.
• W3026111010 hasConceptScore W3026111010C2776107976 @default.
• W3026111010 hasConceptScore W3026111010C2776178377 @default.
• W3026111010 hasConceptScore W3026111010C2777701055 @default.
• W3026111010 hasConceptScore W3026111010C2778378633 @default.
• W3026111010 hasConceptScore W3026111010C2779013556 @default.
• W3026111010 hasConceptScore W3026111010C2780192828 @default.

• next